glp-1 medications market 2025 Trends and Global Forecasts Report 2025: A GLP-1 Market Trends and Global

We selected SGLT-2 inhibitors and DPP-4 inhibitors as active comparators, because they are used at a similar disease stage as GLP-1 and are not associated with the outcome

We cannot exclude the possibility that GLP-1 or GIP receptor number or sensitivity could influence responses to ligands or antagonists of those receptors

Intriguingly, a recent randomised controlled trial found that metformin significantly improved depressive symptoms in patients with treatment-resistant bipolar depression [134]

80 Outside of the context of type 2 diabetes, liraglutide has proven successful in causing significant weight loss when administered over 20 weeks to obese, non-diabetic patients